Donor Recruitment and Patient-Derived Cells

Since their development, induced pluripotent stem cells (iPSCs) have become an increasingly useful tool in drug discovery. However, accessing clinical material from the relevant patient population can prove challenging. If you cannot locate human tissue for reprogramming, we can ethically source fresh clinical material for you through our global procurement network.

1. Patient Recruitment – with over 25 years of experience in the biobank sector, REPROCELL operates an extensive human tissue network. Through our clinical partnerships, we can access a diverse range of donors with a full-medical and drug history.

2. Next-Generation Sequencing – screening for donors who meet your genetic criteria is achieved via our broad portfolio of Next Generation Sequencing (NGS) services. This includes, but is not limited to, whole genomic and exome sequencing plus targeted region sequencing. With these advanced screening techniques, we can access donors who can fulfill your specific research needs. You can read more about our NGS capabilities in our portfolio of genomic services.

3. Dynamic Reprogramming – our laboratory team are available 24 hours a day to collect fresh tissue samples once they are made available. With REPROCELL’s latest-generation reprogramming technology, our scientists can derive human iPSCs from fibroblasts, blood, and even urine to fulfill your unique research needs.

Example Case Study: Alzheimer’s disease

REPROCELL’s unique Alzheimer’s disease (AD) model was established from relevant donor fibroblasts. Through our clinical partnerships, patients with AD were identified. After obtaining informed consent, donor blood samples were then screened for the R62H mutant variant of the Presenilin 2 (PS2) gene and fibroblasts were collected from the relevant patient. Following reprogramming, these iPSCs were subsequently differentiated into neurons and then expanded and characterized (Figure 1).

Bibliography

1. Anderson et al. An Induced Pluripotent Stem Cell Patient Specific Model of Complement Factor H (Y402H) Polymorphism Displays Characteristic Features of Age‐Related Macular Degeneration and Indicates a Beneficial Role for UV Light Exposure. Stem Cells 35:11 (2017).
2. Bidollari et al. Generation of induced pluripotent stem cell line, CSSi004-A (2962), from a patient diagnosed with Huntington's disease at the pre-symptomatic stage. Stem Cell Research 28 (2018).
3. Calado et al. Generation of a human iPS cell line from a patient with retinitis pigmentosa due to EYS mutation. Stem Cell Research 33 (2018).
4. Cao et al. Generation of a Urine-Derived Ips Cell Line from a Patient with a Ventricular Septal Defect and Heart Failure and the Robust Differentiation of These Cells to Cardiomyocytes via Small Molecules. Cell Physiology and Biochemistry 50:2 (2018).
5. Ciampi et al. Generation of two isogenic iPS cell lines (IRFMNi002-A and IRFMNi002-B) from a patient affected by Focal Segmental Glomerulosclerosis carrying a heterozygous c.565G>A mutation in PAX2 gene. Stem Cell Research 33 (2018).
6. Fleischer et al. Generation of two induced pluripotent stem cell (iPSC) lines from p.F508del Cystic Fibrosis patients. Stem Cell Research 29 (2018).
7. Gridina et al. Allele-Specific Biased Expression of the CNTN6 Gene in iPS Cell-Derived Neurons from a Patient with Intellectual Disability and 3p26.3 Microduplication Involving the CNTN6 Gene. Molecular Neurobiology 55:8 (2018).
8. Ifuku et al. Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells. Methods in Molecular Biology 1828 (2018).
9. Kahnounova et al. Generation of human iPSCs from human prostate cancer-associated fibroblasts IBPi002-A. Stem Cell Research 33 (2018).
10. Kamath et al. Virus-free and oncogene-free induced pluripotent stem cell reprogramming in cord blood and peripheral blood in patients with lung disease. Regenerative Medicine 13:8 (2018).
11. Kasai-Brunswick et al. Generation of patient-specific induced pluripotent stem cell lines from one patient with Jervell and Lange-Nielsen syndrome, one with type 1 long QT syndrome and two healthy relatives. Stem Cell Research 31 (2018).
12. Kuramoto et al. Generation of Fabry cardiomyopathy model for drug screening using induced pluripotent stem cell-derived cardiomyocytes from a female Fabry patient. Journal of Molecular Cell Cardiology 121 (2018).
13. Limia et al. Characterization of a human induced Pluripotent Stem (iPS) cell line (INCABRi002-A) derived from a primary myelofibrosis patient harboring the 5-bp insertion in CALR and the p.W146X mutation in TP53. Stem Cell Research 33 (2018).
14. Majolo et al. Notch signaling in human iPS-derived neuronal progenitor lines from Focal Cortical Dysplasia patients. International Journal of Developmental Neuroscience 69 (2018).
15. Matsubara et al. Analysis of mitochondrial function in human induced pluripotent stem cells from patients with mitochondrial diabetes due to the A3243G mutation. Scientific Reports 8:949 (2018).
16. Navaroo et al. Modeling cancer using patient-derived induced pluripotent stem cells to understand development of childhood malignancies. Cell Death Discovery 1:4:7 (2018).
17. Osaki et al. Microphysiological 3D model of amyotrophic lateral sclerosis (ALS) from human iPS-derived muscle cells and optogenetic motor neurons. Science Advances 4:10 (2018).
18. Peitz et al. Blood-derived integration-free iPS cell line UKBi011-A from a diagnosed male Alzheimer’s disease patient with APOE ɛ4/ɛ4 genotype. Stem Cell Research 29 (2018).
19. Rotundo et al. Generation of the induced pluripotent stem cell line CSSi006-A (3681) from a patient affected by advanced-stage Juvenile Onset Huntington’s Disease. Stem Cell Research 29 (2018).
20. Sasaki-Honda et al. A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4. Human Molecular Genetics 27:23 (2018).
21. Sun et al. Modeling hallmark pathology using motor neurons derived from the family and sporadic amyotrophic lateral sclerosis patient-specific iPS cells. Stem Cell Research & Therapy 9:315 (2018).
22. Taoka et al. Using patient-derived iPSCs to develop humanized mouse models for chronic myelomonocytic leukemia and therapeutic drug identification, including liposomal clodronate. Nature Scientific Reports 8:15855 (2018).
23. Vallejo-Diez et al. Generation of two induced pluripotent stem cells lines from a Mucopolysaccharidosis IIIB (MPSIIIB) patient. Stem Cell Research 33 (2018).
24. Vigont et al. Patient-Specific iPSC-Based Models of Huntington’s Disease as a Tool to Study Store-Operated Calcium Entry Drug Targeting. Frontiers in Pharmacology (2018).
25. Wuriyanghai et al. Complex aberrant splicing in the induced pluripotent stem cell-derived cardiomyocytes from a patient with long QT syndrome carrying KCNQ1-A344Aspl mutation. Heart Rhythm 15:10 (2018).

Speak to our experts